No photo of Antonio Avallone

View Scopus Profile

Antonio Avallone

  • 2109 Citations
  • 23 h-Index
1992 …2019
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Antonio Avallone is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 6 Similar Profiles
Colorectal Neoplasms Medicine & Life Sciences
oxaliplatin Medicine & Life Sciences
Rectal Neoplasms Medicine & Life Sciences
Fluorouracil Medicine & Life Sciences
irinotecan Medicine & Life Sciences
Stomach Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1992 2019

18F-FDG PET/CT Is an Early Predictor of Pathologic Tumor Response and Survival to Preoperative Radiochemotherapy with Bevacizumab in High Risk Locally Advanced Rectal Cancer

Avallone, A., Aloj, L., Pecori, B., Caraco, C., De Stefano, A., Tatangelo, F., Silvestro, L., Granata, V., Bianco, F., Romano, C., Di Gennaro, F., Budillon, A., Petrillo, A., Muto, P., Botti, G., Delrio, P. & Lastoria, S., Mar 15 2019, In : Journal of Nuclear Medicine.

Research output: Contribution to journal › Article

Fluorodeoxyglucose F18
Chemoradiotherapy
Rectal Neoplasms
Survival
Neoplasms
1 Citation (Scopus)

A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study

Loupakis, F., Intini, R., Cremolini, C., Orlandi, A., Sartore-Bianchi, A., Pietrantonio, F., Pella, N., Spallanzani, A., Dell'Aquila, E., Scartozzi, M., De Luca, E., Rimassa, L., Formica, V., Leone, F., Calvetti, L., Aprile, G., Antonuzzo, L., Urbano, F., Prenen, H., Negri, F. & 24 others, Di Donato, S., Buonandi, P., Tomasello, G., Avallone, A., Zustovich, F., Moretto, R., Antoniotti, C., Salvatore, L., Calegari, M. A., Siena, S., Morano, F., Ongaro, E., Cascinu, S., Santini, D., Ziranu, P., Schirripa, M., Buggin, F., Prete, A. A., Depetris, I., Biason, P., Lonardi, S., Zagonel, V., Fassan, M. & Di Maio, M., Sep 1 2019, In : European Journal of Cancer. 118, p. 121-130 10 p.

Research output: Contribution to journal › Article

Colorectal Neoplasms
Confidence Intervals
Survival
Life Expectancy
L-Lactate Dehydrogenase

Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: The CIFRA study protocol

Ottaiano, A., Scala, S., Normanno, N., Napolitano, M., Capozzi, M., Rachiglio, A. M., Roma, C., Trotta, A. M., D'Alterio, C., Portella, L., Romano, C., Cassata, A., Casaretti, R., Silvestro, L., Nappi, A., Tafuto, S., Avallone, A., De Stefano, A., Tamburini, M., Picone, C. & 13 others, Petrillo, A., Izzo, F., Palaia, R., Albino, V., Amore, A., Belli, A., Pace, U., Di Marzo, M., Chiodini, P., Botti, G., De Feo, G., Delrio, P. & Nasti, G., Sep 9 2019, In : BMC Cancer. 19, 1, 899.

Research output: Contribution to journal › Article

Open Access
irinotecan
Antibody-Dependent Cell Cytotoxicity
Colorectal Neoplasms
oxaliplatin
Therapeutics

Diagnostic performance of gadoxetic acid-enhanced liver MRI versus multidetector CT in the assessment of colorectal liver metastases compared to hepatic resection

Granata, V., Fusco, R., de Lutio di Castelguidone, E., Avallone, A., Palaia, R., Delrio, P., Tatangelo, F., Botti, G., Grassi, R., Izzo, F. & Petrillo, A., Jul 24 2019, In : BMC Gastroenterology. 19, 1, p. 129

Research output: Contribution to journal › Article

Multidetector Computed Tomography
Magnetic Resonance Imaging
Neoplasm Metastasis
Liver
Colorectal Neoplasms

Folfiri-aflibercept vs. Folfiri-bevacizumab as second line treatment of RAS mutated metastatic colorectal cancer in real practice

Ottaiano, A., Capozzi, M., Tafuto, S., De Stefano, A., De Divitiis, C., Romano, C., Avallone, A. & Nasti, G., Jan 1 2019, In : Frontiers in Oncology. 9, AUG, 766.

Research output: Contribution to journal › Article

Open Access
Colorectal Neoplasms
Therapeutics
aflibercept
Bevacizumab
Survival